Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SDI-118 in Elderly Participants With Cognitive Decline
NCT05199142Phase 1Terminated
- Sponsor
- Syndesi Therapeutics
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity comparing SDI-118 with Placebo (2 arms). Primary endpoints: Number of participants with Adverse Events at 17 days, Number of participants with laboratory value abnormalities at 17 days and 7 more. Started Sep 2021; status: terminated.
02
Drugs
plosaracetam
03
Conditions
No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on NCT05199142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199142.